BioXcel Therapeutics (BX20) Stock Overview
Together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
BX20 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioXcel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$5.80 |
| 52 Week Low | US$1.26 |
| Beta | 0.20 |
| 1 Month Change | -0.76% |
| 3 Month Change | -17.09% |
| 1 Year Change | -70.90% |
| 3 Year Change | -99.70% |
| 5 Year Change | -99.83% |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| BX20 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.0% | 0.4% | -0.4% |
| 1Y | -70.9% | -22.6% | 9.4% |
Return vs Industry: BX20 underperformed the German Biotechs industry which returned -5.2% over the past year.
Return vs Market: BX20 underperformed the German Market which returned 9.7% over the past year.
Price Volatility
| BX20 volatility | |
|---|---|
| BX20 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: BX20's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine BX20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 37 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
BioXcel Therapeutics, Inc. Fundamentals Summary
| BX20 fundamental statistics | |
|---|---|
| Market cap | €29.23m |
| Earnings (TTM) | -€57.71m |
| Revenue (TTM) | €636.19k |
Is BX20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BX20 income statement (TTM) | |
|---|---|
| Revenue | US$752.00k |
| Cost of Revenue | US$964.00k |
| Gross Profit | -US$212.00k |
| Other Expenses | US$68.00m |
| Earnings | -US$68.21m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.12 |
| Gross Margin | -28.19% |
| Net Profit Margin | -9,070.61% |
| Debt/Equity Ratio | -122.7% |
How did BX20 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 11:32 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioXcel Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |